Intervention

Adalimumab

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 80 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials80

Recruiting5

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)NCT06996652 · 2026-08-17

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 DiabetesNCT07061574 · 2026-03-10

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyNCT07138898 · 2025-12-12

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisNCT06972446 · 2025-06-20

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseNCT03414502 · 2007-12-10

Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid ArthritisNCT06016517 · 2026-09-01

NOT_YET_RECRUITING

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)NCT06527534 · 2024-07-15

Diabetes Islet Preservation Immune TreatmentNCT02586831 · 2024-06-01

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT05814627 · 2023-06-15

Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISENCT05090124 · 2022-11-04

Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid ArthritisNCT05502731 · 2022-10-01

Yuflyma® (Adalimumab), Patient Experience After SwitchingNCT05427942 · 2022-06-03

Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.NCT05153200 · 2022-01-01

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to MethotrexateNCT04909801 · 2021-09-15

ACTIVE_NOT_RECRUITING

Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug MonitoringNCT04194827 · 2020-03-01

Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease ActivityNCT04222920 · 2020-03-01

Effects of Abatacept on Myocarditis in Rheumatoid ArthritisNCT03619876 · 2019-07-10

A Real-world Study of Imraldi® UseNCT04089514 · 2019-06-30

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)NCT03823391 · 2019-03-27

One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort StudyNCT03662919 · 2018-07-02

Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and TaiwanNCT03505008 · 2018-04-18

Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGationNCT03100253 · 2018-03-01

Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid ArthritisNCT03110094 · 2017-03-13

RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid ArthritisNCT03016260 · 2016-12-01

Immunoregulatory Mechanisms of Treg Cells Induced by TocilizumabNCT02963402 · 2016-11-09

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)NCT02833350 · 2016-09-09

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateNCT02889796 · 2016-08-30

Treatments Against RA and Effect on FDG-PET/CTNCT02374021 · 2016-07-01

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in ChinaNCT02668640 · 2016-05-01

Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)NCT02750800 · 2016-04-07

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexateNCT02629159 · 2015-12-01

ACTIVE_NOT_RECRUITING

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid ArthritisNCT02557100 · 2015-11-19

Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RANCT03172325 · 2015-11-18

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).NCT02480153 · 2015-06-25

Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to MethotrexateNCT02393378 · 2015-04-08

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)NCT02332590 · 2015-01-28

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) SubjectsNCT02198651 · 2015-01-05

The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) PatientsNCT02150473 · 2014-10-01

A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to MethotrexateNCT02097264 · 2014-09-01

Targeted Ultrasound in Rheumatoid ArthritisNCT02056184 · 2013-12-01

Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid ArthritisNCT01970475 · 2013-10-01

Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint DiseaseNCT01893996 · 2013-07-01

Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisNCT02132234 · 2013-06-01

Bone Resorption, Osteoclastogenesis and AdalimumabNCT02035800 · 2013-05-01

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus MethotrexateNCT01764997 · 2013-04-01

Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical PracticeNCT01768858 · 2013-02-05

Stopping TNF Alpha Inhibitors in Rheumatoid ArthritisNCT01793519 · 2013-01-01

Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical PracticeNCT01736189 · 2012-10-11

A Study in Moderate to Severe Rheumatoid ArthritisNCT01710358 · 2012-10-01

Doppler Evaluation in RA Patients After Adalimumab.NCT01609205 · 2012-10-01

Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.NCT01561313 · 2012-03-01

A Crossover Study of the Safety and Tolerability of Two Formulations of AdalimumabNCT01502423 · 2012-01-01

An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha TherapyNCT01592292 · 2011-11-01

SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.NCT01295151 · 2011-08-01

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to MethotrexateNCT01373151 · 2011-06-01

Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-StudyNCT02092961 · 2011-02-01

Efficacy and Safety of Adalimumab 80 mg Every Other Week With MethotrexateNCT01270035 · 2011-01-01

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)NCT01185288 · 2010-09-01

Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep ApneaNCT01181570 · 2010-09-01

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid ArthritisNCT01119859 · 2010-05-01

Common conditions

Leading sponsors

AbbVie 8 Abbott 6 AbbVie (prior sponsor, Abbott) 5 Biogen 3 Bristol-Myers Squibb 3 Hoffmann-La Roche 2 Keio University 2 National Institute of Allergy and Infectious Diseases (NIAID) 2 Pfizer 2 Reade Rheumatology Research Institute 2 Sanofi 2 Université de Sherbrooke 2 Amgen 1 AstraZeneca 1 Brigham and Women's Hospital 1

Trial status mix

COMPLETED50

UNKNOWN11

TERMINATED9

RECRUITING5

ACTIVE_NOT_RECRUITING2

WITHDRAWN2

NOT_YET_RECRUITING1

Phase mix

PHASE428

PHASE321

PHASE216

NA3

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.